Contrave fluctuates obesity treatment market led by Belviq
Like the last year’s Belviq, new obesity treatments approved by the FDA are expected to fluctuate the domestic obesity treatment market.
According to the Ministry of Food and Drug Safety on the 2nd, Kwang Dong Pharmaceutical’s diet pill, ‘Contrave ER Tab(naltrexone+bupropion),’ was domestically ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
